Impact empagliflozin on glycemic control in patients with diabetes mellitus type 2 with ischemic heart disease prior to elective percutaneous coronary intervention

• Khorlampenko A.A.
• Kochergina A.M.
• Ignatova Yu.S.

Abstract

Diabetes meLLitus (DM) is a dangerous disease with the deveLopment of severe compLications Leading to earLy disabiLity and mortaLity. Coronary heart disease (CHD) in diabetes is characterized by rapidLy progressive muLti-vesseL Lesion of coronary arteries with a tendency to invoLvement of the distaL segments of the coronary arteries. The widespread introduction into cLinicaL practice of percutaneous coronary intervention have improved Long-term prognosis of coronary heart disease. At the same time, patients with CHD in combination with diabetes meLLitus type 2 after coronary revascuLarization are at increased risk of restenosis, and repeated endovascuLar interventions. Appointment ampicipLin in addition to standard antidiabetic therapy may Lead to improved outcomes of revascuLarization in patients with concomitant diabetes meLLitus type 2. Studied the effectiveness of gLycemic controL when using ampicipLin in patients with CHD in combination with diabetes meLLitus type 2, to eLective percutaneous coronary intervention. Given the interim resuLts of a prospective study.

The majority of patients with diabetes meLLitus type 2, directed to the pLanned endovascuLar revascuLarization of the myocardium have poor gLycemic controL (according to HbA_1c).

Short-term appointment empagLifLozin (10 mg/day) in addition to the basic hypogLycemic therapy for 1 month increases the number of patients with adequate gLycemic controL.

Keywords:diabetes mellitus type 2, coronary heart disease, percutaneous coronary intervention, ampiciplin, glycemic control

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)